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Typically there are three categories for 
Hyperthermia, including local, regional and whole 
body (1). Local Hyperthermia is used to 
solid ,localized and superficial tumors while regional 
is generally used for deeper diseases, and whole 
body Hyperthermia typically used for metastatic 
cancers (2). Whole body hyperthermia devices uses 
water-filtered infrared radiation (wIRA) emitters  by 
four wIRA emitters to the upper zone, and two 
WIRc emitters  for warming the lower limb of 
patients (3). The most common method in whole 
body hyperthermia is used of infrared chamber (4).  
Other methods may administrate through patient ,s 
room or warping the patient in heated blanket (1). 
Actually the exact mechanism of direct HT-induced 
cell death is not well understood (5).  
 Hyperthermia refers to elevation tumor temperature from 39 up to 43 degree 
Celsius. Actually Therapeutic Hyperthermia has been used as an adjuvant 
treatment for cancer, since end of the 19th century after observations William 
Coley who found that tumor is diminished after induction of fever by bacterial 
toxins. Hyperthermia therapy refers to treatment tumors through heating which 
has been used since the time of the ancient Egyptians. The term ‘Hyperthermia’ 
in oncology means treatment of malignant disease by heating in different ways. 
Hyperthermia is usually applied as an adjuvant therapy method in combination 
with other modalities such as Radiotherapy or Chemotherapy in cancer 
treatment. Typically there are three categories for Hyperthermia, including 
local, regional and whole body. Based on the temperature Whole body 
hyperthermia classify in 3 type, mild, fever range and extreme. In Mild 
hyperthermia, the temperature is from 37.5 up to 38.5 degree Celsius, in fever 
range hyperthermia, 38.5 up to 40 degree Celsius, and extreme hyperthermia, 
the temperature above 40 degree Celsius. Now Days Whole body hyperthermia 
known as immunotherapy related to cancer treatment in oncology. Here we will 
review whole body hyperthermia related to cancer treatment. 
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Mechanisms of Action of Hyperthermia 
Actually the exact mechanism of direct HT-induced 
cell death is not well understood (5). Certainly 
clinical effects of Hyperthermia is more Based on it 
's combination with other modalities, and it is more 
important, it can sensitize tumor cells to other forms 
of therapy, including RT (Radiation Therapy) and 
chemotherapy (CT).  Molecular effectors of 
hyperthermia include; Cell membrane alterations in 
fluidity, stability, changes in structure; stability of 
plasma membrane, membrane potential, cell surface 
receptors, transmembrane transport mechanisms, 
apoptosis, impairment of ion transport (Ca2+, Na+, 
Mg+, K+); impairment of protein synthesis, Induction 
of HSP synthesis, generation of reactive oxygen 
species (ROS), impairment of RNA/DNA synthesis, 
inhibition of DNA-repair mechanisms, modification 
of gene expression, signal transduction Inhibition of 
DNA repair enzymes, and protein synthesis 
(impaired), miss folding, denaturation /nuclear 
aggregation  (6-9). Although the role of HSPs is still 
under investigation, current evidence has proved that 
enhanced immunogenicity and HSP expression seen 
after tumor cells are heated, thermally enhanced 
immune effector cell activation and function, 
thermally enhanced vascular perfusion and delivery 
or trafficking of immune effector cells to tumors (10, 
11). Due to their unique immunologic features, 
HSPs are induced by hyperthermia known as 
specific immunogenic effectors (12, 13). To regard 
as many Studies that  have demonstrated 
immunological effects of fever range whole-body 
hyperthermia (FR-WBH), The most important role 
of elevation temperature in fever range is 
immunological  effects.  It is now appreciated that 
heating tumors (in situ) can activate vascular, 
metabolic, and immunologic parameters of the 
tumor microenvironment which may play an 
additional role in radiochemosensitization beyond 
hyperthermia induced cell killing of tumor cells (14, 
15). The extent of the interaction of heat and 
radiation can be expressed in terms of the thermal 
enhancement ratio (TER), defined as the ratio of 
doses of x-rays required to produce a given level of 
biologic damage with and without the application of 
heat. TER  have been estimated to be in range of 1.5 
for several human tumor  type.  Jones and colleagues 
reported that mild hyperthermia (41° and 41.5° C at 
90% of the measured points for 1 hour) significantly 
increased the po2 in hypoxic.  
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Such increases in tumor oxygenation could 
significantly improve tumor response to 
radiotherapy and is likely to be the primary 
important effect of local/regional or whole   body 
forms of clinical hyperthermia.   
‘Thermalradiosensitization’  results in a reduction of 
the shoulder of the dose–effect curve. It appears 
most pronounced in S-phase cells that are usually 
resistant to radiation  alone . Also  HT  can increase 
perfusion to tumors, making them more susceptible 
to RT and increasing cell-killing (16).  
 
Clinical Use of Hyperthermia 
   A randomized clinical trial carried out by Jones et 
al-2005,Has reported  CR rates of 23.5% for 
radiotherapy  alone versus 68.2% for hyperthermia 
plus radiotherapy (4). To regard as many studies that  
have demonstrated immunological effects of fever 
range whole-body hyperthermia (FR-WBH) , the 
most important role of elevation temperature in fever 
range is immunological effects (5). Although the 
role of HSPs is still under investigation, much more 
work is needed, current evidence has proved that 
enhanced immunogenicity and HSP expression seen 
after tumor cells are heated, thermally enhanced 
immune effector cell activation and function, 
thermally enhanced vascular perfusion and delivery 
or trafficking of immune effector cells to tumors(10, 
11). Based on Table 1, Several phase III trials 
exploring HT with RT have been performed since 
the 1980s and are published but neither phase III 
studies of local nor whole body have been done on 
the whole body hyperthermia for metastatic 
cancers .Just  phase I study by Bell et al. explored 
the application of whole body Hyperthermia plus CT 
using an infrared radiant heating device as part of a 
regimen which included cisplatin, gemcitabine, and 
INF-a for chemotherapy-resistant metastatic or other 
advanced solid malignancies (4). In Phase I/II 
studies at University of Texas, Medical School at 
Houston,  fever range hyperthermia plus 
chemotherapy ,at April 2008 that  career out  JM 
Bull et al ,the good response were observed in 
patients with high grade neoroendocrine and 
pancreas cancer. The complete and partial responses 
combined  were 43 % (17). A more recent trial from 
Duke University Medical Center randomized 
patients between RT and HT + RT for superficial 
tumors≤3 cm in depth. Tumors were mostly in the 
breast and chest wall region (64%), but also included  
Figure1:The interaction between Hyperthermia and immune system based on  Repasky ‘s study. 
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Table 1. Ligands with corresponding cancerous cell surface specific antigens 
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head and neck (13%), melanomas (10%), and other 
regions (12%) (4, 18, 19). A randomized clinical 
trial carried out by Jones et al-2005 Has reported 
that CR rates of 23.5% for RT alone versus68.2% 
for HT + RT. At now a large number of studies 
document effectiveness of clinical effectiveness of 
hyperthermia plus RT or CT in vivo whether or in 
vitro condition, and also several clinical trial studies 
comparing have shown beneficial effects of 
hyperthermia with RT and or CT.  In spite of many 
studies about HT , mechanism of it is unclear (5). 
Also  HT  can increase perfusion to tumors, making 
them more susceptible to RT and increasing cell-
killing (16). Such increases perfusion to tumors 
could significantly improve tumor response to 
radiotherapy and is likely to be the primary 
important effect of local/regional or whole body 
forms of clinical hyperthermia (4).  
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hyperthermia can be used in combination with other modalities such as radiation therapy or chemotherapy that 
can have additive effect on the modalities. Actually  a large number of studies document  clinical 
effectiveness of hyperthermia in combination with RT or CT in vivo and/or in vitro condition.  In spite of 
many studies which has been published about HT, at now the exact mechanism of it is unclear. Here we 
review type of method and description of cellular basic of hyperthermia related to cancer treatment and 
summaries the clinical data have been documented  effects of hyperthermia in combination with other 
modalities. Despite of many study up to now, the actual mechanism of hyperthermia related to cancer 
immunology effects is unclear, so much more work is needed to understood this interaction. 
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